Protara Therapeutics公司公布了其正在进行的二期Advanced-2试验的最新积极数据。数据显示,针对BCG初治型非肌层浸润性膀胱癌(NMBC)患者,TARA-002治疗在完全入组的患者队列中,展现了长达12个月的持久治疗反应。
此次更新的12个月数据进一步验证了TARA-002在该患者群体中的潜力。试验结果持续显示出良好的疗效信号,为后续临床开发提供了有力支持。该消息增强了市场对Protara Therapeutics核心管线产品前景的信心。
Protara Therapeutics公司公布了其正在进行的二期Advanced-2试验的最新积极数据。数据显示,针对BCG初治型非肌层浸润性膀胱癌(NMBC)患者,TARA-002治疗在完全入组的患者队列中,展现了长达12个月的持久治疗反应。
此次更新的12个月数据进一步验证了TARA-002在该患者群体中的潜力。试验结果持续显示出良好的疗效信号,为后续临床开发提供了有力支持。该消息增强了市场对Protara Therapeutics核心管线产品前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.